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Dengue Fever: An Overview
Ramalingam Kothai and Balasubramanian Arul
Abstract
Dengue fever is a disease caused by a family of viruses transmitted by mosquitoes. 
Dengue virus (DENV), a member of the Flaviviridae family, causes the most 
widespread mosquito-borne viral infection in humans around the world today. 
Dengue can affect anyone but tends to be more severe in people with compromised 
immune systems. Dengue hemorrhagic fever is a more severe form of a viral illness. 
Symptoms include headache, fever, rash, and evidence of bleeding (hemorrhage) in 
the body. This form of dengue fever can be life-threatening and can progress to the 
most severe form of the illness, dengue shock syndrome. This chapter reviews the 
etiology, epidemiology, diagnosis, pathophysiology, transmissions, manifestations, 
diagnosis, treatment, and prevention of dengue.
Keywords: dengue, etiology, epidemiology, pathophysiology
1. Introduction
Dengue fever is a mosquito-borne viral infection which has a sudden onset that 
follows symptoms such as headache, nausea, weakness, intense muscle and joint 
pain, swelling of lymph nodes (lymphadenopathy), and rashes on the skin. Many 
symptoms of dengue fever include gingivitis, sharp pain in the eyes, and swollen 
palms and soles.
Dengue can affect any person but appears to be more serious in immunocom-
promised people. Because it is caused by one of the five dengue virus serotypes, it is 
possible to have dengue fever multiple times. Nonetheless, a dengue attack provides 
lifelong immunity to the specific viral serotype to which the patient has been 
exposed. This disease may also be called “breakbone fever” or “dandy fever.”
This dengue fever may become more serious and then named as dengue hemor-
rhagic fever and dengue shock syndrome. Dengue hemorrhagic fever is a more severe 
form in which hemorrhages occurs in the body. It is a life-threatening condition, and 
it may progress to the most critical form called dengue shock syndrome [1].
2. Etiology
Dengue virus (DENV) is a single-stranded, positive-sense RNA virus in the 
Flaviviridae family and the Flavivirus genus. When viewed under the transmission 
electron micrograph, the virions appear as a bunch of black spots. Yellow fever 
virus, West Nile virus, St. Louis encephalitis virus, Japanese encephalitis virus, tick-
borne encephalitis virus, Kyasanur Forest disease virus, and Omsk hemorrhagic 
fever virus belong to this family, and majority of them is transmitted by arthropods 
(mosquitoes or ticks) [2].
Please use Adobe Acrobat Reader to read this book chapter for free.
Just open this same document with Adobe Reader.
If you do not have it, you can download it here.
You can freely access the chapter at the Web Viewer here.
Securing Connection...Acrobat is locking documen loading.com
r
File cannot be found.
Dengue Fever in a One Health Perspective
2
Approximately 11,000 nucleotide bases were present in the dengue genome, which 
codes for a single polyprotein. It is made up of three structural protein molecules (C, 
prM, and E) that constitute the virus particle and seven nonstructural proteins (NS1, 
NS2a, NS2b, NS3, NS4a, NS4b, and NS5) which are required for viral replication [3, 4]. 
The five strains of the virus (DENV-1, DENV-2, DENV-3, DENV-4, and DENV-5) are 
referred to as serotypes because they vary in serum reactivity (antigenicity) [5].
The main cause of dengue fever is an infected mosquito bite [6], and besides it, 
it may be accidentally acquired after vertical transmission, especially in near-term 
pregnant women through the placenta [7], infected blood products [8], through 
organ transplantation [9], and even after needle stick injury [10].
3. Epidemiology
Awareness about the terrestrial spread and impact of dengue is relevant for 
assessing its relation to worldwide morbidity and mortality and knowing how to 
utilize the available resources for controlling the dengue globally.
Only nine countries had suffered major epidemics of dengue, before 1970. 
Currently it is common in most of the regions of the WHO. The Americas, South 
East Asia, and Western Pacific areas are the most severely affected, with Asia 
responsible for around 70% of the global disease burden. Throughout the recent 
decades, the prevalence of dengue has significantly elevated around the globe. The 
vast majority of cases are asymptomatic or mild and self-managed, and therefore 
the actual number of dengue cases is underreported. Many cases are also misdiag-
nosed as other febrile disorders [11].
One report indicates 390 million dengue virus infections per year, of which 96 
million occur clinically (with any disease severity). The report on dengue prevalence 
reports that 3.9 billion people are at risk of infection with dengue viruses. Despite the 
risk of infection in 128 countries, 70% of the real burden is from Asia [12].
The number of dengue cases recorded to WHO has risen ~6 fold, from <0.5 
million in 2010 to more than 3.34 million in 2016. The year 2016 was marked by 
massive dengue outbreaks worldwide. A major reduction in the number of dengue 
cases in the Americas was reported in 2017, from 2,177,171 cases in 2016 to 584,263 
cases in 2017. It reflects a drop of 73%. Following a drop in the number of cases in 
2017–2018, a sharp increase in cases is reported in 2019. Cases have increased in 
Australia, Cambodia, China, Lao PDR, Malaysia, the Philippines, Singapore, and 
Vietnam. An estimated 500,000 people with severe dengue require hospitalization 
every year, and an estimated 2.5% of cases are fatal each year. Nevertheless, several 
countries have lowered the case fatality rate to less than 1%, and internationally, 
there has been a decline in case of fatality between 2010 and 2016, with a significant 
improvement in case management through country-level capacity building. The 
only continent that has not witnessed dengue transmission is Antarctica.
The global burden of dengue is formidable and is a growing challenge for public 
health officials and policymakers. Success in addressing this growing global threat 
depends, in part, on strengthening the evidence base on which planning control 
decisions and their impact are assessed. It is hoped that this assessment of the distri-
bution and burden of contemporary dengue risk will help to advance this objective.
4. Pathophysiology
The pathophysiology of DENV and the immune response of the host are 
not fully understood. Primary manifestations of disease include capillary leak 
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syndrome (plasma leakage due to DHF-specific endothelial cell dysfunction), 
thrombocytopenia (seen in all types of DENV infection, but extreme in DHF), 
hemorrhagic tendencies, and leukopenia. It is known that the major viral enve-
lope (E) of glycoprotein in the virus helps to bind the host cells, followed by viral 
replication [13] . Data suggest that monocytes are the primary target [14]. Infected 
monocytes induce the production of interferon-a (IFN-a) and IFN-b [15]. Envelope 
(E), precursor membrane protein (pre-M), and nonstructural protein 1 (NS1) 
are the major DENV proteins targeted by antibodies as part of the host immune 
response. Studies have shown that DENV-specific CD4+ and CD8+ T lymphocytes 
attack infected cells and release IFN-g, tumor necrosis factor-a (TNF-a), and 
lymphotoxin. Primary infection induces a lifetime immunity of the individual to 
that particular serotype, but not to secondary infection by another serotype.
5. Transmission
Dengue virus is the most common mosquito-borne infection in humans all over the 
world. It belongs to the family Flaviviridae, which contains more than 70 viruses [16], in 
which DENV is transmitted by the Aedes aegypti and Aedes albopictus mosquitoes [17].
Dengue virus is spread primarily by Aedes mosquitoes, in particular Aedes aegypti. 
These mosquitoes usually live between 35°N and 35°S below an altitude of 1000 m 
(3300 feet) [5]. They usually bite especially in the early morning and in the evening. 
Certain Aedes disease-borne species include Aedes albopictus, Aedes scutellaris, and 
Aedes polynesiensis. Human beings are the primary hosts of this virus, arousing even 
nonhuman primates. An infection may be obtained through a single bite. A female 
mosquito that consumes an infected person’s blood (within a febrile, viremic span of 
2 to 12 days) becomes infected with the virus in its intestine. The virus then spread 
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into other tissues, including the salivary glands of the mosquito, approximately after 
a period of 8–10 days and is subsequently released into its saliva. When it bites the 
other person, the virus is transmitted through its saliva to that person. The virus does 
not cause any harm to the mosquito [18]. Aedes aegypti is a main concern as it prefers 
to lay its eggs in containers of freshwater and stay close to humans. Infected blood 
products and organ donation can also cause dengue [8, 9, 19]. Even in countries 
like Singapore, the incidence is approximately 1.6 to 6 in 10,000 transfusions [20]. 
The vertical transmission (from mother to child) during pregnancy or at birth is 
also documented [8]. Other person-to-person forms of transmission have also been 
reported, but are very rare [21]. Dengue’s genetic variants are regionally specific, 
indicating that the creation of new territories is relatively rare, despite the fact that 
dengue has appeared in new regions in recent decades [22].
5.1 The virus
DENV is a small single-stranded RNA virus consisting of five different serotypes 
(DENV-1 to DENV-5). The virus particle is spherical in shape with a diameter of 
50 nm. The genome is divided into three structural proteins (capsid C prM, mem-
brane precursor M protein, and envelope E) and seven nonstructural proteins (NS) 
by the host and viral proteases.
Within each serotype, distinct genotypes or lineages (viruses closely related in 
nucleotide sequence) have been identified, demonstrating the substantial genetic 
variability in dengue serotypes. However, purifying selection continues to be a 
dominant theme in the evolution of dengue viruses, so only viruses that are “fit” 
for both humans and vectors are retained. Between these, severe secondary dengue 
infections are often associated with “European” genotypes DENV-2 and DENV-3 
[23–25]. The human hosts have established intra-host viral diversity (quasi-species).
5.2 The vectors
Different dengue virus serotypes are transmitted to humans through the bites 
of infected Aedes mosquitoes, mainly Aedes aegypti. This mosquito is a tropical 
and subtropical species widely distributed around the world, mostly between 
35°N and 35°S latitudes. Such geographical limits correspond roughly to the 10°C 
winter isotherm. Aedes aegypti was located as far north as 45°N, but in warmer 
months, these invasions took place, and the mosquitoes did not survive the winter 
months. Aedes aegypti is also relatively uncommon over 1000 m, due to lower 
temperatures. The embryonic stages are found in water-filled settings, mostly in 
artificial containers that are closely linked to human dwellings, and often inside. 
Research suggests that mostly female Aedes aegypti may spend their lives in or 
around the homes where the adults emerge. It means people are spreading the virus 
quickly within and between populations, rather than mosquitoes. Aedes albopictus, 
Aedes polynesiensis, and several species of Aedes scutellaris were also attributed 
to outbreaks of the dengue [26]. Each of these species has a specific ecological, 
behavioral, and geographical distribution. Aedes albopictus has spread from Asia to 
Africa, Americas, and Europe in recent decades, aided particular by international 
trade in used tires, where eggs are deposited as they contain rainwater. Eggs can 
remain viable for many months, in the absence of water.
5.3 The host
After an incubation period of 4–10 days, infection with any of the four 
virus serotypes can cause a wide range of illnesses, although most infections are 
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asymptomatic or subclinical. Primary infection is thought to cause long-term 
defensive immunity to serotype infections [27]. Around 2–3 months of primary 
infection, but without long-term cross-protective immunity, individuals suffering 
from infection are protected from clinical illness with a specific serotype.
Personal risk factors influence the severity of the disease and also include 
secondary infections (bronchial asthma, sickle cell anemia, and diabetes mellitus), 
age, race, and potentially chronic diseases. In particular, young children may be less 
able to compensate for capillary leakage than adults and are thus at a higher risk of 
dengue shock [5].
Seroepidemiological reports conducted in Cuba and Thailand strongly support 
the position of secondary heterotypic infection as a risk factor for severe dengue, 
although there is little evidence of serious primary infection cases [28–31]. Also, 
the time interval between infections and the specific viral infection sequence may 
be significant. For example, a higher fatality rate was observed in Cuba when DEN2 
infection followed DEN-1 infection at an interval of 20 years compared to 4 years. 
Severe dengue is also commonly seen in infants born to dengue-infected mothers. 
Antibody-dependent enhancement (ADE) of the infection has been hypothesized 
[32] as a mechanism to explain severe dengue in the course of secondary infection 
and in infants with primary infections. In this model, non-neutralizing, cross-
reactive antibodies produced during primary infection or acquired passively at birth 
bind to epitopes on the surface of the heterologous infective virus and promote the 
entry of the virus into Fc-bearing cells. The increased number of infected cells is 
expected to result in increased viral load and robust host immune response activa-
tion including inflammatory cytokines and mediators, some of which may contrib-
ute to capillary leakage. Cross-reactive memory T cells are also rapidly triggered 
during secondary infection, proliferate, release cytokines, and die of apoptosis in 
a manner that usually correlates with overall disease severity. Host genetic deter-
minants may have an effect on the clinical outcome of infection [33], although 
most studies have not been able to address this problem adequately. Studies in the 
American region indicate that the levels of extreme dengue in individuals of African 
descent are lower than in other ethnic groups [34].
Recent data suggest that endothelial cell activation could mediate plasma leakage 
[35, 36]. Plasma leakage is believed to be associated with functional effects on 
endothelial cells, rather than harmful ones. Endothelial cell dysfunction may also 
be associated with the activation of infected monocytes and T cells, the comple-
ment system, and the production of mediators, monokines, cytokines, and soluble 
receptors.
Thrombocytopenia may be associated with alterations in megacaryocyto-
poiesis due to human hematopoietic cell infection and impaired progenitor 
cell growth, resulting in platelet dysfunction (activation and aggregation of 
platelets), increased destruction, or consumption (peripheral sequestration and 
consumption). Hemorrhage may result from thrombocytopenia and related plate-
let dysfunction or intravascular coagulation. In short, a transient and reversible 
imbalance of inflammatory mediators, cytokine, and chemokine occurs during 
severe dengue times, probably due to high early viral loads, leading to vascular 
endothelial cell dysfunction, hemocoagulation disorders, and then plasma 
 leakage, shock, and bleeding.
6. Manifestations
One of three clinical forms can be used in humans, such as dengue fever (DF), 
dengue hemorrhagic fever (DHF), and dengue shock syndrome (DSS).
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Approximately one-half of the DENV infections are asymptomatic, and some 
are undifferentiated (in which the patient develops fever and mild symptoms, but 
the source of the infection is not diagnosed as DENV). The three clinical forms 
of the disease vary in the severity of their symptoms, with the influenza-like DF 
being the least severe and the DSS being the most severe. In most cases, mild febrile 
DF is not fatal; however, infections that develop into DHF or DSS may be life-
threatening and cause death in many cases. Patients with DHF and DSS were found 
to have virus titers 100- to 1000-fold higher than those with DF from the initial 
stage of infection [37]. Overall, DENV infection has been found to be more severe 
in children than adults [38].
Based on the outcome of several studies, the WHO has developed a new dengue 
classification. It differentiates dengue cases into cases with or without warning 
signs and serious cases of dengue.
Usually, signs begin to appear after an incubation period of 3–10 days [39]. The 
severity of clinical presentations ranges from mild symptoms to extreme life-threat-
ening symptoms for dengue hemorrhagic fever and dengue shock syndrome [40]. 
Predicting the progression of mild signs to severe DHF/DSS remains a challenge due 
to unspecific clinical presentation and incomplete understanding of disease patho-
physiology and its underlying molecular mechanisms.
The early signs of the disease are nonspecific. According to WHO, DF is char-
acterized by febrile episodes (≥40°C for 2–7 days) often associated with rash, 
nausea, vomiting, and headache. Even though the disease affects all ages of people 
from infant to adulthood [41], epidemiological data showed that children tend to 
control this disease better than adults [42]. The severity of the above symptoms 
and the emergence of other symptoms, such as abdominal pain, mucosal bleeding, 
and lethargy and restlessness, can be seen after 3–7 days. Laboratory examination 
of mild dengue fever cases usually reveals elevated leukocyte counts and a small 
increase in hepatic aminotransferase activity. The emergence of these symptoms is a 
warning sign of disease progression to severe form (DHF/DSS) if therapeutic action 
is not undertaken. At this level, clinical intervention and continuous surveillance 
are necessary to prevent vascular leakage, especially in the endemic region.
Extreme dengue infection can be due to any of the four recognized DENV 1–4 
serotypes. The likelihood of developing DHF/DSS is high in patients who have had 
dengue infection with heterogeneous serotype [43] in the past, with approximately 
5–10% of patients developing extreme DHF/DSS that can be fatal unless treated 
promptly [44].
This type evolves at a late stage of DF, where patients will experience a defer-
vescent process characterized by a sudden drop in body temperature. This phase 
is also characterized by severe bleeding, especially from the gastrointestinal tract 
(black, tarry stool) and thrombocytopenia (<50,000/mm3), which may affect up 
to 50% of DHF cases [45]. Ironically, there was a negative correlation between the 
frequency of DHF and the number of platelets in the blood. The exact mechanism 
of this association is yet to be identified. Decreased platelet counts and loss of func-
tion contribute to vascular fragility, increasing the risk of hemorrhage and plasma 
leakage59. It has been proposed that DENV replicates rapidly in platelets during the 
acute phase of infection, as this is very important to the survival and dissemination 
of the virus [46]. The existence of other signs such as retro-orbital pain, macu-
lopapular rash, petechiae, or nose or gum bleeding may help to make a definitive 
diagnosis of DF [47]. Subsistence in systolic pressure and hypotension can result in 
profound shock, known as dengue shock syndrome. Long-term DSS duration can 
predispose to additional complications such as severe bleeding, diffuse intravascu-
lar coagulopathy (DIC), respiratory failure, multiorgan failure, and infrequently 
encephalopathy leading to death [48, 49]. It was estimated that DHF-related case 
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fatality could exceed 15% of all cases, but proper medical treatment and symptom-
atic management could minimize the mortality rate to less than 1%.
Signs and symptoms depending on the stage of the disease reflect the dengue 
fever. People with dengue virus normally become asymptomatic (80%) or have 
mild symptoms such as uncomplicated fever [50, 51]. 5 % of the people have more 
severe illness and, in a small proportion of cases (<1%), are life-threatening and 
cause death despite care. The incubation period (time between exposure and onset 
of symptoms) ranges from 3 to 14 days, but most of the time is 4 to 7 days. Children 
are more likely to have atypical symptoms, often with common cold or gastroenteri-
tis (vomiting and diarrhea)-like symptoms [52].
The characteristic symptoms of dengue are sudden fever, headache (typically 
behind the eyes), muscle and joint pain, and rash. The course of infection is divided 
into three phases: febrile, serious, and recovery. The febrile phase includes high fever, 
possibly over 40°C (104°F) and is associated with severe pain and headache; this 
period usually lasts 2–7 days. Vomiting and rash will be there along with flushed skin. 
In some cases, the illness is progressing to a serious stage as the fever clears. This pro-
cess is characterized by major, diffuse plasma leakage usually lasting 1–2 days. Organ 
dysfunction and severe bleeding, usually from the gastrointestinal tract, may also 
occur [53]. Shock (dengue shock syndrome) and hemorrhage (dengue hemorrhagic 
fever) occur in less than 5% of all dengue cases. This serious phase is more common 
among children and young adults. The recovery phase is followed by the resorption of 
the leaked fluid into the bloodstream over a duration of 2–3 days. The change is often 
startling and can be followed by serious pruritus and bradycardia. The rash can occur, 
with either a maculopapular or a vasculitic appearance accompanied by desquama-
tion. A fluid-overloaded condition can occur during this stage, in rare cases.
Dengue also affects a variety of other body systems, either in isolation or along 
with typical dengue symptoms. Decreased sensitivity occurs in 0.5–6% of severe 
cases, due to encephalitis or, indirectly, to compromised vital organs (e.g., hepatic 
encephalopathy). Other neurological disorders similar to dengue, such as transverse 
myelitis and Guillain-Barré syndrome, have been identified. Myocarditis and acute 
liver failure are among the most rare complications.
7. Diagnosis
Signs and symptoms of dengue fever are similar to some other illnesses, such as 
typhoid fever or malaria, which can sometimes hinder the likelihood of a timely and 
correct diagnosis. It may be diagnosed by the patient’s signs and symptoms, patient’s 
medical history, and testing blood samples (preliminary by platelet count, followed 
by ELISA, HI assay, and RT-PCR).
The early and precise diagnosis of dengue infection in the laboratory is of para-
mount importance for disease control. It was estimated that the number of cases of 
dengue misdiagnosed could reach a record of 50% of all cases, mainly due to a wide 
disparity in dengue signs and symptoms that conflict with symptoms of other viral 
infections, particularly for people living in or traveling to endemic areas of tropi-
cal infectious diseases. Until the antiviral vaccine is available, early and accurate 
diagnosis relies heavily on the prevention of serious cases and the reduction of the 
disease’s economic burden. To date, two screening methods have been employed for 
early diagnosis of the disease. The first is a direct approach for the acute dengue dis-
ease phase which is focused on an antigen detection of genomic RNA from viremic 
patient’s blood samples. The second is an indirect approach that relies on serological 
tests to detect dengue-related immunoglobulins by Mac-ELISA for the capture of 
real IgM or indirect ELISA for the capture of antiDEN IgGs.
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Dengue diagnosis is usually performed clinically on the basis of recorded symp-
toms and physical examination, especially in endemic areas. However, early dengue 
fever can be difficult to differentiate from other viral infections. Tourniquet testing, 
which is particularly useful in environments where laboratory tests are not available, 
includes applying a blood pressure cuff, inflating it to the midpoint between diastolic 
and systolic pressure for 5 minutes, and then counting any petechial hemorrhages 
that occur. The higher number of petechiae makes dengue diagnosis more likely; the 
lower limit for diagnosis is variably specified as 10–20 petechiae per 2.5 cm2 [54].
8. Treatment
There are no particular antiviral medicines for dengue, but it is necessary to 
maintain a proper fluid balance [55]. Treatment is dependent on the severity of 
the symptoms. Those who can drink and pass urine have no warning signs can be 
treated with daily follow-up and oral rehydration therapy at home. Those who have 
serious health problems, who have warning signs, or who are unable to handle daily 
follow-up should be admitted to the hospital for treatment. For areas with access 
to an intensive care unit, treatment should be given for those with extreme dengue 
fever. Intravenous hydration usually takes 1 or 2 days, if necessary. Fluid adminis-
tration dose is titrated to 0.5–1 mL/kg per hour of urinary output, stabilizing vital 
signs, and normalizing hematocrit. The volume of fluid that is provided should be 
the smallest to achieve such markers. Bearing in mind the risk of infection, invasive 
medical procedures such as nasogastric intubation, intramuscular injections, and 
arterial punctures should be avoided. Paracetamol (acetaminophen) is used for 
fever and nausea, and it is important to avoid nonsteroidal anti-inflammatory drugs 
such as ibuprofen and acetylsalicylic acid as they may increase the risk of bleeding. 
For patients with compromised vital signs faced with declining hematocrit, blood 
transfusion should begin early, rather than waiting for the concentration of hemo-
globin to decline to some predetermined “cause of transfusion” level. It is advised 
to deliver red blood cells or whole blood; platelets and fresh, frozen plasma are not 
typically recommended. Intravenous fluids are removed during the recovery phase 
to avoid fluid overload. When fluid overload occurs and vital signs are stable, stop-
ping the administration of fluid can be all that is required to remove excess fluid. If 
the individual is outside the critical phase, a diuretic loop, such as furosemide, may 
be used to remove excess fluid from circulation.
9. Prevention
In December 2015, after decades of research and clinical progress, the first 
dengue vaccine (CYD-TDV or Dengvaxia®, by Sanofi Pasteur) was authorized 
[56]. Now regulatory authorities have approved it in ~20 countries.
CYD-TDV was found to be effective and safe in clinical trials in people who had 
past infections with the dengue virus (seropositive individuals). It does, however, 
bring an increased risk of severe dengue in those who undergo their first normal den-
gue infection after vaccination (those who were seronegative at vaccination time). It 
was confirmed in November 2017 by the results of an additional retrospective study 
analysis which determines the serostatus at the time of vaccination.
Pre-vaccination screening is the recommended strategy for countries which con-
sider vaccination as part of their dengue control program. With this approach only 
individuals under evidence of past dengue infection would be vaccinated (based on 
an antibody test or confirmed dengue infection in the past by a verified laboratory). 
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Decisions on implementing a pre-vaccination screening strategy would require care-
ful country-level evaluation, including consideration of the sensitivity and specificity 
of the available tests and local priorities, dengue epidemiology, country-specific 
hospitalization levels, and availability of both CYD-TDV and screening tests [57].
But prevention depends on the monitoring and safety of the bite of the mosquito 
that transmits it. The primary tool used to monitor Aedes aegypti is by destroying its 
habitats, which include standing water in urban areas (e.g., abandoned tires, ponds, 
irrigation ditches, and open barrels). If habitat destruction is not possible, the applica-
tion of insecticides or biological control agents to standing water is another option. 
Reducing open water collection is the preferred and simplest method of control. 
Generalized spraying is often done with organophosphate or pyrethroid insecticides 
but is not considered successful. People can avoid mosquito bites by wearing clothes 
that completely cover the skin, wearing a repellent scarf, or staying in air-conditioned, 
screened, or nested areas. However, these approaches do not seem to be sufficiently 
effective, as the frequency of outbreaks in certain areas appears to be increasing, prob-
ably because urbanization is increasing the habitat of Aedes mosquitoes; however, the 
range of diseases appears to be expanding, possibly due to climate change.
10. Conclusion
Dengue fever is a terrible disease and a growing public health problem. A rapid 
increase in unplanned urbanization leads to more mosquito breeding sites, hence 
a greater number of people are exposed to Aedes Aegypti mosquitoes bite. These 
include semi-urban and slum areas where household water storage is normal and 
where solid waste disposal facilities are inadequate. The urgent need for a vaccine 
to minimize morbidity and mortality due to this disease has been recognized in a 
cost-effective manner in recent years.
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